<DOC>
	<DOCNO>NCT00266591</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety topiramate ( antiepileptic medication ) patient epilepsy .</brief_summary>
	<brief_title>A Study Efficacy Safety Topiramate Treatment Patients With Epilepsy</brief_title>
	<detailed_description>Epilepsy disease characterize seizure , abnormal electrical discharge brain temporarily disrupt normal brain function . Seizures classified `` generalize , '' originate side brain time , `` partial onset , '' start one area brain . Antiepileptic medication , topiramate , select base patient 's seizure type . The specific type seizure always obvious time diagnosis . This randomized , double-blind , parallel-group study evaluate effectiveness safety two dos topiramate ( 100 1000 mg per day ) patient partial onset seizure . The study compose three phase : 8-week baseline phase patient take standard antiepileptic drug , 1-week open-treatment phase patient continue standard antiepileptic drug add topiramate ( 100 mg/day ) , double-blind treatment phase . The double-blind phase divide two period : 5-week conversion period 11-week treatment period topiramate . In conversion period , patient gradually discontinue baseline antiepileptic drug . Those assigned topiramate 1000 mg/day group start take 100 mg/day dose gradually increase 1000 mg/day ( maximum tolerate dose ) 5-week period . Patients assign topiramate 100 mg/day receive one 100 mg tablet ( plus placebo tablet maintain blind 5 week period ) . Patients group continue dose 11-week treatment period . Patients provide diary record information regard seizure occur study . The primary assessment effectiveness amount time patient receives topiramate double-blind treatment phase exit ( withdraw ) study . Four exit criterion withdrawal design correspond therapeutic failure ensure subject safety : ) double average monthly ( 28-day ) seizure frequency compare baseline ; ii ) double high two-day seizure frequency occur baseline ; iii ) single generalized seizure none occur baseline phase ; iv ) prolongation generalize seizure duration ( serial seizure status epilepticus ) compare baseline phase seizure duration require intervention . Safety assessment study include frequency severity adverse event , result clinical laboratory test ( hematology , biochemistry , urinalysis ) , blood gastrin level , measurement vital sign body weight , patient global evaluation study drug tolerability , neurologic examination , neuropsychologic test , physical examination finding . Based investigator 's judgment , patient complete study could enrol open-label extension phase , patient know identity dose topiramate . The study hypothesis 1000 mg/day dose topiramate superior 100 mg/day dose amount time patient exit ( withdraw base pre-established exit criterion correspond therapeutic failure ) double-blind phase . 100 mg/day group : one Topiramate 100 mg oral tablet ( plus placebo tablet maintain blind ) 16 week . 1000 mg/day group : start one Topiramate 100 mg oral tablet gradually increase 1000 mg/day ( maximum tolerate dose ) 5 week , continue dose 11 week .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Body weight &gt; 90 pound documented history frequent partial onset seizure least four partial onset seizure per month take constant antiepileptic drug dosage screening period recent history maintenance 1 2 standard antiepileptic drug female must postmenopausal least 1 year , childbearing age , sexually abstinent , surgically sterile , use adequate birth control measure , negative pregnancy test study entry . Patients epilepsy , patient treatable cause seizure ( example , cancer active infection ) document history ( previous 3 month ) generalize status epilepticus receive anticonvulsant medication ( status epilepticus prolong seizure seizure repeat frequently 20 30 minute recovery episode occur ) seizures occur cluster pattern ( numerous seizure short period time ) significant history ( within 2 year ) medical disease ( heart , kidney , hormone , gynecologic , muscle , bone , gastrointestinal , metabolic , liver disease cancer metastatic potential ) history alcohol drug abuse history within past 1 year .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Seizures</keyword>
	<keyword>Topiramate</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Antiepileptic</keyword>
	<keyword>Epileptic seizure</keyword>
	<keyword>Partial seizure disorder</keyword>
	<keyword>Brain disease</keyword>
</DOC>